In the News: US Lawmakers Seek Increased Scrutiny of US Clinical Drug Trials in China; China Eases Foreign Investment Rules; and Wealth Connect Scheme Expanded

U.S. lawmakers call on the government to scrutinize drugmakers' clinical trials in China; China removes restrictions for foreign investments in the manufacturing and services industries; and Cross-Boundary Wealth Connect gains 10 new additional securities firms for increased offshore investment opportunities.

5 minute readAugust 28, 2024 at 05:18 AM

Clarence Lee, Brian Chan

& Krista Lee

US Drugmakers' Clinical Trials in China Under Scrutiny

A bipartisan group of U.S. lawmakers sent a letter to the U.S. Food and Drug Administration last week, asking that it increase scrutiny of U.S. clinical trials conducted in China, according to Reuters.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English

✓ Newsletters with business-critical and sector-specific updates

✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now